Holen Sie sich die Stockscreener-App
30.22
1.96%
0.58
Newamsterdam Pharma Company Nv Aktie (NAMS) Neueste Nachrichten
NAMS|NewAmsterdam Pharma Company NV|Price:30.190|Chg%:+0.550 - TradingKey
NewAmsterdam Pharma Company NV (NAMS) Income Statement - TradingKey
TradingKey - TradingKey
NewAmsterdam Pharma says EU CHMP backs approval of Ubeslo, Evlarco cholesterol drugs - Bitget
NewAmsterdam Pharma Company NV (NAMS) Cash Flow - TradingKey
NewAmsterdam Pharma Company NV (NAMS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
NewAmsterdam Pharma: Obicetrapib Is More Than Another LDL-Lowering Pill - Seeking Alpha
NAMS|NewAmsterdam Pharma Company NV|Price:29.640|Chg%:-0.910 - TradingKey
NewAmsterdam says EU CHMP backs Ubeslo, Evlarco cholesterol drugs for approval - Bitget
NewAmsterdam Pharma (NAMS) Slides 2.98% as Biotech Sector Faces HeadwindsNews Sentiment - dars.gov.et
How EMA’s Positive CHMP Opinion on Ubeslo and Evlarco at NewAmsterdam Pharma (NAMS) Has Changed Its Investment Story - simplywall.st
NewAmsterdam and Menarini Receive Positive CHMP Opinion for Ubeslo and Evlarco - Intellectia AI
EQS-News: NewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)boerse.de - boerse.de
NewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination) - recnews.it
Newamsterdam Pharma Company N.V. and Menarini Group Receives Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo (Obicetrapib Monotherapy) and Evlarco (Obicetrapib Plus Ezetimibe Fixed-Dose Combination) - marketscreener.com
NewAmsterdam Pharma Wins EMA Backing for Obicetrapib Therapies - TipRanks
NewAmsterdam Pharma gets positive CHMP opinion for obicetrapib-based Ubeslo and Evlarco, EC decision due 2H26 - TradingView
NewAmsterdam Pharma and Menarini Group Receive Positive - GlobeNewswire
NewAmsterdam Pharma Company NV (NAMS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
NewAmsterdam Pharma Company (NAMS) Q1 2026 earnings summary - Quartr
NewAmsterdam Pharma Announces COO Transition and Advisory Role - TipRanks
NewAmsterdam Pharma's COO Douglas Kling to Leave for CEO Role at Another Clinical-Stage Biotech Company - Kalkine Media
Form 4 NewAmsterdam Pharma Co N.V. For: 22 July By Investing.com - Investing.com Nigeria
NewAmsterdam Pharma (NAMS) COO Douglas Kling to step down Aug 14 - Stock Titan
NewAmsterdam Pharma (NAMS) CAO trades 105000 shares under 10b5-1 plan - Stock Titan
NewAmsterdam Pharma Company N.V. Announces Resignation of Douglas Kling from Chief Operating Officer, Effective August 14, 2026 - marketscreener.com
Enterprise value to revenue forward of NewAmsterdam Pharma Company N.V. – NASDAQ:NAMS - TradingView
Enterprise value to revenue forward of NewAmsterdam Pharma Company N.V. – SWB:KH6 - TradingView
NewAmsterdam Pharma Company (NAMS) Citi Annual Global Healthcare Conference 2025 summary - Quartr
Jefferies reiterates NewAmsterdam Pharma stock rating ahead of data - Investing.com UK
Jefferies reiterates NewAmsterdam Pharma stock rating ahead of data By Investing.com - Investing.com Nigeria
Responsive Playbooks and the NAMS Inflection - Stock Traders Daily
NewAmsterdam Pharma publishes obicetrapib Alzheimer’s prevention research presentation - Bitget
Enterprise value to revenue forward of NewAmsterdam Pharma Company N.V. – MUN:KH6 - TradingView
Price-Driven Insight from (NAMSW) for Rule-Based Strategy - Stock Traders Daily
NewAmsterdam Pharma (NAMS) Drops 5.6% as Selling Pressure IntensifiesLarge Cap Trends - dars.gov.et
Price to sales forward of NewAmsterdam Pharma Company N.V. – NASDAQ:NAMS - TradingView
NewAmsterdam Pharma (NAMS) Dips Amidst Sector Rotation; Key Support in FocusFundamental Weighted - dars.gov.et
NewAmsterdam Pharma to Present Obicetrapib Alzheimer’s Data - t.co
NewAmsterdam Pharma (NAMS) Alzheimer’s Data Push Puts Fair Value Back In Focus - Sahm
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sahm
NAMSNewAmsterdam Pharma Company NV Latest SEC Filings - Finviz
(NAMSW) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
NewAmsterdam Pharma Announces Upcoming Presentations at the Alzheimer's Association International Conference (AAIC) 2026 - marketscreener.com
NewAmsterdam Pharma Company N.V. - TradingView
Price to sales forward of NewAmsterdam Pharma Company N.V. – BOATS:NAMSW - TradingView
Enterprise value to revenue forward of NewAmsterdam Pharma Company N.V. – BOATS:NAMSW - TradingView
Enterprise value to revenue forward of NewAmsterdam Pharma Company N.V. – NASDAQ:NAMSW - TradingView
Enterprise value to EBIT forward of NewAmsterdam Pharma Company N.V. – NASDAQ:NAMSW - TradingView
Price to sales forward of NewAmsterdam Pharma Company N.V. – NASDAQ:NAMSW - TradingView
Price to book forward of NewAmsterdam Pharma Company N.V. – NASDAQ:NAMSW - TradingView
Understanding the Setup: (NAMS) and Scalable Risk - Stock Traders Daily
Price to book forward of NewAmsterdam Pharma Company N.V. – NASDAQ:NAMS - TradingView
Price to book forward of NewAmsterdam Pharma Company N.V. – LSX:A3DUAC - TradingView
NewAmsterdam Pharma Company N.V. Actuals & Estimates (NASDAQ:NAMS) - TradingView
NAMS Forecast — Price Target — Prediction for 2027 - TradingView
NewAmsterdam Pharma Company N.V. Actuals & Estimates (MUN:KH6) - TradingView
Enterprise value to EBITDA forward of NewAmsterdam Pharma Company N.V. – NASDAQ:NAMS - TradingView
Enterprise value to revenue forward of NewAmsterdam Pharma Company N.V. – LSX:A3DUAC - TradingView
NewAmsterdam Pharma Company N.V. Actuals & Estimates (LSX:A3DUAC) - TradingView
Enterprise value to EBIT forward of NewAmsterdam Pharma Company N.V. – NASDAQ:NAMS - TradingView
1.97%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):